[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-cancer-metastatic\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-cancer-metastatic":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,53,77,100,121,151],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":36,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100575356","phase-1-slv-154-treatment-of-metastatic-solid-tumors-100575356",false,"NCT06771219","SLV-154 Treatment of Metastatic Solid Tumors","A Phase 1 Dose-Escalation Study of SLV-154 in Subjects With Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Men or women (as appropriate for cancer type) of age ≥18 years.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.\n3. Histologically or cytologically confirmed diagnosis of solid tumor as documented in medical records with the primary history comprising one of the following:\n\n   1. SCCHN\n   2. NSCLC\n   3. SCLC\n   4. Breast cancer\n   5. Cervical cancer\n   6. Endometrial cancer\n   7. Ovarian cancer\n   8. Urothelial cancer\n   9. Sarcoma\n   10. Thyroid cancer\n4. Presence of metastatic disease that has progressed during or following previous treatment.\n5. Presence of radiographically measurable disease.\n6. Prior receipt of commercially available therapies that are indicated for the subject's cancer and have demonstrated survival benefit for that indication.\n7. Availability of tumor tissue from a fresh tumor biopsy obtained by a core needle, excisional, or incisional biopsy; or punch biopsy (for cutaneous disease); or archival tumor sample from a previous biopsy.\n8. Availability of computed tomography (CT) or magnetic resonance imaging (MRI) of chest, abdomen, and pelvis, and\u002For fluorodeoxyglucose (FDG) positron emission tomography (PET)\u002FCT (if appropriate for tumor type) (with PET from base of the skull to mid-thigh, if performed) within 35 days before study drug administration.\n9. Completion of all previous therapy (including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥1 week before the start of study drug administration.\n10. Adequate hematological profile.\n11. Adequate coagulation profile.\n12. Adequate hepatic profile.\n13. Adequate renal function.\n14. Negative viral serology or adequate therapy for human immunodeficiency virus (HIV), hepatitis B (HBV), and hepatitis C (HCV) infection.\n15. For female subjects of childbearing potential, a negative serum pregnancy test.\n16. For female subjects of childbearing potential, willingness to use a protocol-recommended method of contraception from the start of the screening period until ≥6 months after the final dose of study therapy.\n17. For male subjects who can father a child and are having intercourse with females of childbearing potential who are not using adequate contraception, willingness to use a protocol-recommended method of contraception from the start of study therapy until ≥6 months after the final dose of study therapy and to refrain from sperm donation from the start of study therapy until ≥12 months after administration of the final dose of study therapy.\n18. Willingness and ability of the subject to comply with scheduled visits, the drug administration plan, protocol-specified laboratory tests, other study procedures (including required tumor biopsy\u002Faspirations and\u002For radiographic studies), and study restrictions.\n19. Evidence of a personally signed informed consent indicating that the subject is aware of the neoplastic nature of the disease and has been informed of the procedures to be followed, the experimental nature of the therapy, alternatives, potential risks and discomforts, potential benefits, and other pertinent aspects of study participation.\n\nExclusion Criteria:\n\n1. Malignancy involving the central nervous system unless brain metastases have been previously treated with radiotherapy, have been stable for ≥4 weeks, and do not require corticosteroids.\n2. Presence of another cancer with disease manifestations or therapy that could adversely affect subject safety or longevity, create the potential for drug-drug interactions, or compromise the interpretation of study results.\n3. Uncontrolled ongoing systemic bacterial, fungal, or viral infection (including upper respiratory tract infection) at the time of start of study therapy.\n4. Significant cardiovascular event or comorbidity.\n5. Significant screening ECG abnormalities.\n6. Pregnancy or breastfeeding.\n7. Major surgery within 4 weeks before the start of study therapy.\n8. Use of a strong inhibitor or inducer of CYP3A4 or CYP1A2.\n9. Use of a drug known to prolong the QT interval within 7 days prior to the start of study drug administration.\n10. Concurrent participation in another therapeutic or imaging clinical trial.\n11. Other conditions likely to interfere with a subject's ability to participate in the study.","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.",[26,27,28,29,30,31,32,33,34,35],"Squamous Cell Cancer of Head and Neck (SCCHN)","NSCLC","SCLC","Cervical Cancer Metastatic","Breast Cancer Metastatic","Endometrial Cancer","Ovarian Cancer","Urothelial Cancer","Sarcoma","Thyroid Cancer",[37,38,39],"metastatic solid tumors","metastatic cancer","solid tumor","RECRUITING","2026-06-29",{"date":43,"type":44},"2026-06-30","ACTUAL",{"date":46,"type":44},"2025-05-14",{"date":48,"type":20},"2027-04",{"name":50,"class":51},"Solve Therapeutics","INDUSTRY",10,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":21,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100623086","phase-3-a-phase-iii-clinical-study-of-wx390-combined-with-toripalimab-versus-investigators-choice-of-therapy-in-patients-with-recurrent-or-metastatic-cervical-cancer-who-have-failed-prior-platinum-based-treatment-100623086","NCT07392060","A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment","A Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment","Inclusion Criteria:\n\n1. The subject voluntarily participates in this clinical study, has provided signed informed consent prior to the initiation of any screening procedures, and is able to understand and comply with the study requirements.\n2. Aged 18 to 75 years (inclusive, calculated on the day of signing the informed consent form).\n3. Histologically or cytologically confirmed cervical cancer, including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.\n4. Not eligible for curative treatment with surgery, radiotherapy, or chemoradiotherapy.\n\n   Willing to undergo a biopsy during the screening period to provide fresh tumor tissue for PD-L1 and PIK3CA mutation testing; if a biopsy is not feasible, archived tumor tissue samples (formalin-fixed, paraffin-embedded (FFPE) blocks or unstained FFPE slides) may be provided for PD-L1 testing. All testing will be performed at a central laboratory. If the provided tumor tissue sample is deemed unsuitable by the central laboratory for evaluating PD-L1 expression and\u002For PIK3CA mutation status, the subject cannot be enrolled.\n5. Must have at least one measurable lesion as per RECIST v1.1 criteria. Previously irradiated lesions with confirmed progression on imaging may be considered as target lesions.\n6. ECOG performance status of 0 or 1.\n7. Able to swallow tablets normally.\n8. Life expectancy of ≥3 months.\n\nExclusion Criteria:\n\n1. Previous treatment with any PI3K, AKT, or mTOR inhibitor, or prior treatment with toripalimab.\n2. Patients with type 1 or type 2 diabetes mellitus.\n3. History of interstitial lung disease, drug-induced pneumonitis, pulmonary fibrosis, pneumoconiosis, or radiation pneumonitis (patients with only radiographic evidence of radiation pneumonitis and not requiring corticosteroid therapy may be enrolled). Patients with active pneumonia during screening, severely impaired lung function, or other conditions that may interfere with the detection and management of suspected drug-related pulmonary toxicity.\n4. Radiographic evidence of tumor invasion into the bladder or rectum, deemed by the investigator to pose a risk of perforation; or a known history of female reproductive tract fistula (e.g., vesicovaginal fistula, urethrovaginal fistula, cervicovesical fistula, etc.). Patients may be enrolled if the perforation or fistula has been treated with diversion surgery, resection, or repair, and the condition is considered resolved or controlled by the investigator.\n5. Currently active bleeding, intra-abdominal abscess, or intestinal obstruction requiring clinical intervention.\n6. CT\u002FMRI or other imaging shows tumor invasion or encasement of major blood vessels, indicating a high risk of bleeding.\n7. Current clinically significant hydronephrosis. Patients may be enrolled if hydronephrosis is relieved by nephrostomy or ureteral stent placement.\n8. Patients with refractory nausea and vomiting, dysphagia, gastrointestinal disorders affecting drug absorption (e.g., Crohn's disease, ulcerative colitis, or short bowel syndrome), or other malabsorption conditions.\n9. History of severe allergy, hypersensitivity, or other anaphylactic reactions to the investigational product or any of its excipients.\n10. Administration of a live vaccine within 4 weeks prior to randomization or planned administration during the study.\n11. Patients with active autoimmune disease, history of bone marrow or solid organ transplantation, suicidal tendency, alcohol or drug dependence, clear history of neurological or psychiatric disorders, or other conditions that, in the investigator's assessment, may contraindicate the use of the investigational product, compromise the interpretation of study results, or result in forced discontinuation from the study.","75 Years",{"count":62,"type":20},440,[64],"PHASE3","This is a Randomized, Open-Label, Controlled, Multicenter Phase III Clinical Study to evaluate the efficacy of WX390 in combination with toripalimab versus investigator's choice of therapy in patients with recurrent or metastatic cervical cancer who have failed at least one prior platinum-based systemic therapy, as assessed by overall survival (OS).",[29],"NOT_YET_RECRUITING","2026-02-04",{"date":70,"type":44},"2026-02-06",{"date":72,"type":20},"2026-02-28",{"date":74,"type":20},"2030-06-30",{"name":76,"class":51},"Shanghai Jiatan Pharmatech Co., Ltd",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":83,"minAge":17,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100613419","a-non-interventional-registration-study-of-monotherapy-or-combination-regimens-based-on-camrelizumab-or-famitinib-for-the-treatment-of-cervical-cancer-100613419","NCT07266350","A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer","Inclusion Criteria:\n\n1. Age ≥18 years old;\n2. Sign the informed consent form and voluntarily join this study;\n3. Patients with cervical cancer diagnosed by histopathology;\n4. Receive treatment with monotherapy or combination regimens based on camrelizumab or famitinib;\n5. It is necessary to agree to take effective contraceptive measures and avoid egg donation from the time of signing the informed consent form until 2 months after the last administration of camrelizumab, 3 months after the last administration of famitinib, or within the contraceptive period specified in the instructions of the last administration of other study drugs (whichever is longer).\n\nIf a patient has had menstruation but has not yet reached postmenopausal status (with no menstruation for a continuous period of ≥12 months and no other causes found except menopause), and has not undergone sterilization surgery (such as hysterectomy, bilateral tubal ligation or bilateral oophorectomy), the patient is considered to have fertility.\n\nExclusion Criteria:\n\n1. There is already evidence indicating that the patient is a pregnant or lactating woman.\n2. Currently participating in any research involving intervention measures outside of regular clinical practice;\n3. The researcher determines other circumstances that are not suitable for inclusion in the study.","FEMALE",{"count":85,"type":20},1300,"OBSERVATIONAL","This trial is a national multicenter, open-label, non-interventional study to observe and evaluate the safety and efficacy of monotherapy or combination regimens based on camrelizumab or famitinib in patients with cervical cancer.\n\nThis study included patients with cervical cancer who used monotherapy or combination regimens based on camrelizumab or famitinib. The administration regimens include but are not limited to camrelizumab monotherapy, camrelizumab in combination with mitinib, famitinib monotherapy, camrelizumab in combination with other treatment regimens selected by the investigator, camrelizumab in combination with mitinib and other treatment regimens selected by the investigator, and famitinib in combination with other treatment regimens selected by the investigator.\n\nIt is planned to include cervical cancer patients who have decided to be treated with monotherapy or combination regimens based on camrelizumab or famitinib before enrollment, with an estimated 1,300 cases.\n\nAccording to the treatment plan received by the patients, after enrollment, they can be respectively placed in one of the following six cohorts:\n\nQueue 1: Only receiving camrelizumab monotherapy\n\nQueue 2: Only receiving famitinib monotherapy\n\nQueue 3: Only combination therapy of camrelizumab and famitinib was received\n\nQueue 4: Receiving camrelizumab in combination with other treatment regimens\n\nQueue 5: Receiving famitinib in combination with other treatment regimens\n\nQueue 6: Receiving camrelizumab and famitinib in combination with other treatment regimens\n\nData from the baseline period, treatment period and follow-up period were collected respectively according to the cohort category (prospective or retrospective) of the enrolled patients.",[29,89],"Cervical Cancer Recurrent","2025-12-04",{"date":92,"type":44},"2025-12-05",{"date":94,"type":20},"2025-12-30",{"date":96,"type":20},"2030-12-30",{"name":98,"class":99},"Qi Zhou","OTHER",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":83,"minAge":17,"maxAge":60,"enrollmentInfo":106,"targetDuration":4,"studyType":21,"phases":108,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":4},"100603959","phase-2-a-prospective-randomized-parallel-trial-of-famitinib-malate-at-different-doses-combined-with-camrelizumab-for-the-treatment-of-recurrent-and-metastatic-cervical-cancer-100603959","NCT07143292","A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer","Inclusion Criteria:\n\n1. The subjects voluntarily joined this clinical study and signed the informed consent form, demonstrating good compliance, be able to cooperate with follow-up visits;\n2. Age: 18 to 75 years old (inclusive, calculated from the date of signing the informed consent);\n3. Cervical cancer confirmed by histopathology, including cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;\n4. It cannot be cured by surgery, radiotherapy or chemoradiotherapy;\n5. Those who have received platinum-based systemic therapy for recurrent\u002Fmetastatic cervical cancer; The number of previous systemic treatment lines is ≤2;\n6. Has not received bevacizumab treatment in the past;\n7. It can perform biopsies during the screening period and provide fresh tumor tissues for PD-L1 testing;\n8. According to the RECIST v1.1 standard, the patient must have at least one measurable lesion;\n9. ECOG score: 0-1 point;\n10. Be able to swallow pills normally;\n11. The expected survival period is ≥3 months;\n12. The functions of important organs should meet the standards.\n\nExclusion Criteria:\n\n1. History (within the past 5 years) or concurrent presence of other untreated malignant tumors, except for cured thyroid cancer, basal cell carcinoma, carcinoma in situ, and breast cancer that has been completely resected and has not recurred for more than 3 years;\n2. Individuals who have previously received famitinib or are allergic to other monoclonal antibodies;\n3. Individuals with any active, known autoimmune diseases;\n4. Participants who have received systemic treatment with corticosteroids (prednisone or other equivalent hormones at a dose \\>10 mg\u002Fday) or other immunosuppressive agents within the past 4 weeks. In the absence of active autoimmune disease, inhaled or topical corticosteroids, as well as adrenal hormone replacement therapy at a dose ≤10 mg\u002Fday of prednisone equivalent, are permitted;\n5. Known brain metastases or leptomeningeal metastases (excluding cases with brain metastases that have been stable for ≥4 weeks following radiotherapy or surgery);\n6. Imaging studies at screening showing tumor invasion of the bladder or rectum, with an assessed risk of perforation by the investigator;\n7. Spontaneous vaginal bleeding \\>30 ml\u002Fday within 2 weeks prior to randomization, or visible tumors in the vagina, with a risk of bleeding as assessed by the investigator;\n8. Clinical symptoms of ascites or pleural effusion requiring drainage, or drainage of pleural or abdominal fluid within 2 weeks prior to randomization; excluding cases with imaging showing minimal ascites or pleural effusion without clinical symptoms;\n9. History or current presence of idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation-induced pulmonary inflammation (only radiologically demonstrated, those not requiring steroid treatment may be enrolled), drug-induced pneumonia, or active pneumonia during the screening period that the investigator determines precludes enrollment;\n10. Uncontrolled cardiac symptoms or conditions, such as: (1) NYHA Class 2 or higher heart failure; (2) unstable angina; (3) acute myocardial infarction within the past year; (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention;\n11. Hypertension that is uncontrolled despite antihypertensive medication (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg);\n12. Urinalysis indicating urine protein ≥2+, or quantitative urine protein testing confirming 24-hour urine protein quantification ≥1.0 g;\n13. Currently receiving thrombolytic\u002Fanticoagulant therapy, with prophylactic use of low-dose aspirin (≤100 mg\u002Fday) or low-molecular-weight heparin (≤40 mg\u002Fday);\n14. Patients who experienced any severe bleeding event of grade 2 or higher according to the CTCAE v5.0 criteria within 4 weeks prior to randomization;\n15. Patients with imaging evidence of tumor invasion into major vessels or those deemed by the investigator to have a high likelihood of tumor invasion into major vessels during treatment, potentially leading to life-threatening hemorrhage;\n16. Patients who have experienced intestinal obstruction or required parenteral nutrition within 1 month prior to randomization;\n17. Patients who have experienced arterial or venous thromboembolic events within 6 months prior to randomization, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism, excluding lower extremity intermuscular venous thrombosis that, after assessment, does not require anticoagulant therapy, or thrombosis caused by catheter placement that has resolved and does not require medication;\n18. Known hereditary or acquired bleeding and thrombotic tendencies (such as hemophilia, coagulation disorders, etc.);\n19. Patients with radiation enteritis accompanied by bleeding symptoms, or those judged by the investigator to have a risk of risk of gastrointestinal perforation or bleeding;\n20. Patients who have undergone prior radiotherapy, chemotherapy, or tumor surgery, with less than 4 weeks elapsed from the completion of treatment (last dose) to randomization (for patients with bone metastasis, palliative radiotherapy to an area \\\u003C5% of the bone marrow region may be permitted up to 2 weeks prior to randomization); or patients who have taken oral molecularly targeted drugs within 5 drug half-lives prior to randomization; or adverse reactions (excluding alopecia) that have not recovered to ≤ CTCAE v5.0 Grade 1;\n21. Subjects with active infections, or unexplained fever ≥ 38.5°C within 7 days prior to randomization, or those who have used antibiotics within 7 days prior to randomization;\n22. Subjects with congenital or acquired immune deficiencies (e.g., HIV-infected individuals); or active hepatitis (HBV reference: HBsAg positive and HBV DNA ≥ 500 IU\u002FmL or 1000 copies\u002FmL; for hepatitis C: HCV antibody positive and HCV RNA \\> upper limit of normal);\n23. Received a live vaccine within the previous 4 weeks or may receive one during the study period;\n24. The investigator determines that the subject has other factors that may lead to the study being terminated prematurely, such as severe concomitant diseases (e.g., severe diabetes, spinal cord compression, superior vena cava syndrome, mental illness), severe laboratory abnormalities, or family or social factors that may affect the subject's safety or the collection of data and samples;\n25. Severe non-healing wounds, ulcers, or fractures, or abdominal fistula, gastrointestinal perforation, or abdominal abscess within 6 months prior to randomization.",{"count":107,"type":20},120,[109],"PHASE2","This study is a prospective, randomized, parallel investigation aimed at evaluating different doses of famitinib malate (20mg, 15mg, or 10mg, once daily, respectively) by analyzing the pharmacokinetics, efficacy, safety, and tolerability of famitinib malate combined with camrelizumab at different doses. The feasibility of continuously oral administration combined with camrelizumab in reducing the incidence of adverse events (especially grade ≥3 adverse events) in patients by dose reduction while maintaining comparable efficacy.",[29,89],"2025-11-16",{"date":114,"type":44},"2025-11-18",{"date":116,"type":20},"2025-11-30",{"date":118,"type":20},"2028-06-30",{"name":120,"class":99},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":83,"minAge":17,"maxAge":4,"enrollmentInfo":128,"targetDuration":4,"studyType":21,"phases":130,"briefSummary":131,"conditions":132,"keywords":136,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":4},"100603797","phase-2-ql1706-in-patients-with-recurrent-and-metastatic-cervical-cancer-resistant-to-prior-pd-1pd-l1-antibody-therapy-100603797","NCT07141186","QL1706 in Patients With Recurrent and Metastatic Cervical Cancer Resistant to Prior PD-1\u002FPD-L1 Antibody Therapy","A Prospective, Single-Arm, Phase II Trial of QL1706 in Patients With Recurrent and\u002For Metastatic Cervical Cancer Who Had Developed Resistance to Prior PD-1\u002FPD-L1 Antibody Therapy","Inclusion Criteria:\n\n1. Patients with recurrent\u002Fmetastatic cervical cancer who previously experienced failure of PD-1 blockade therapy;\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;\n3. Life expectancy ≥3 months;\n4. At least one measurable lesion per RECIST v1.1:\n\n   Non-lymph node lesion: Longest diameter ≥10 mm Lymph node lesion: Short-axis diameter ≥15 mm Note: Previously irradiated lesions must be outside radiation fields or demonstrate progression post-radiation.\n5. Adequate organ function within 14 days prior to treatment:\n\n   1. Absolute neutrophil count (ANC) ≥1.0×10⁹\u002FL\n   2. Hemoglobin ≥60 g\u002FL\n   3. Platelet count ≥50×10⁹\u002FL\n   4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3×ULN (≤5×ULN for hepatic metastasis)\n   5. Serum creatinine ≤2×ULN\n6. Reproductive requirements:\n\n   1. Non-childbearing potential (surgically sterilized or postmenopausal) OR\n   2. Women of childbearing potential:\n\n   Negative serum pregnancy test within 7 days prior to enrollment Commitment to use double-barrier contraception throughout the study and for 180 days post-treatment\n7. Ability to comply with scheduled visits, treatment plans, and laboratory tests;\n8. Voluntarily signed written informed consent.\n\nExclusion Criteria:\n\n1. Prior treatment with anti-PD-1\u002FCTLA-4 bispecific antibodies;\n2. Active autoimmune disease requiring systemic control with corticosteroids (≥10 mg\u002Fday prednisone equivalent) or immunosuppressants within 14 days prior to enrollment;\n3. Clinically significant cardiovascular\u002Fcerebrovascular events within 6 months prior to treatment, including:\n\n   1. Acute myocardial infarction\n   2. Unstable angina\n   3. Cerebrovascular accident\n   4. Symptomatic arterial\u002Fvenous thrombosis or ischemic cardiomyopathy\n   5. Clinically significant ventricular arrhythmias (sustained VT, VF, torsades de pointes)\n   6. NYHA Class III\u002FIV heart failure\n   7. QTcF ≥480 ms or congenital long QT syndrome\n   8. LVEF \\\u003C50% or severe wall motion abnormality per echocardiography\n   9. Uncontrolled hypertension (SBP \\>160 mmHg or DBP \\>100 mmHg)\n   10. Other clinically significant arrhythmias (e.g., third-degree AV block);\n4. Uncontrolled comorbidities potentially affecting protocol compliance:\n\n   * Severe respiratory diseases (ILD, severe asthma)\n   * Active infections:\n\n     * HBV (HBsAg+ AND HBV-DNA \\>500 IU\u002FmL)\n     * HCV (HCV-Ab+ AND HCV-RNA+)\n     * HIV-Ab+\n     * Active TB or systemic infections requiring treatment ≤14 days\n   * GI perforation\u002Ffistula ≤6 months (exceptions: resolved surgically)\n   * Clinically significant bleeding ≤1 month (hematemesis, hemoptysis, etc.)\n   * Active diverticulitis, abdominal abscess, or bowel obstruction;\n5. Other malignancies within 3 years (excluding cured BCC, superficial bladder Ca, DCIS, or papillary thyroid Ca);\n6. Known immunodeficiency disorders;\n7. History of allogeneic hematopoietic stem cell or solid organ transplantation (excluding corneal grafts);\n8. Systemic infections requiring IV antibiotics \\>7 days within 2 weeks prior to treatment;\n9. Administration of live attenuated vaccines within 4 weeks before\u002Fafter treatment;\n10. Pregnancy or lactation;\n11. Investigator-assessed ineligibility;\n12. Concurrent participation in other clinical trials.",{"count":129,"type":20},50,[109],"To explore the efficacy and safety of administrating QL1706 in patients with recurrent and\u002For metastatic cervical cancer who had developed resistance to prior PD-1\u002FPD-L1 antibody therapies.",[133,29,89,134,135],"Cervical Cancer","Cervical Adenocarcinoma","Cervical Cancer Squamous Cell",[137,138,139,140,141],"cervical cancer","immunotherapy","PD-1\u002FCTLA-4 bispecific antibody","QL1706","PD-1 resistant","2025-08-25",{"date":144,"type":44},"2025-08-26",{"date":146,"type":20},"2025-10-01",{"date":148,"type":20},"2030-10-01",{"name":150,"class":99},"Tianjin Medical University Cancer Institute and Hospital",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":83,"minAge":17,"maxAge":60,"enrollmentInfo":158,"targetDuration":4,"studyType":21,"phases":160,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":4},"100595696","phase-2-a-single-arm-phase-ii-multicenter-clinical-trial-to-evaluate-the-efficacy-and-safety-of-the-combination-therapy-of-iparomlimab-and-tuvonralima-b-and-chemotherapy--bevacizumab-induction-therapy-followed-by-concurrent-chemoradiotherapy-in-patients-with-advanced-cervical-cancer--100595696","NCT07035808","a Single Arm, Phase II Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of Iparomlimab and Tuvonralima b and Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy in Patients With Advanced Cervical Cancer .","Efficacy and Safety of Iparomlimab and Tuvonralimab(QL1706) Combined With Chemotherapy ± Bevacizumab Induction Therapy Followed by Concurrent Chemoradiotherapy for High-risk Locally Advanced Cervical Cancer：a Single Arm, Phase II Multicenter Clinical Study","Inclusion Criteria:\n\n* 1\\. Sign a written informed consent before any trial-related procedures. 2. Histologically confirmed cervical squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma.\n\n  3\\. Patients with stage Ⅳa confirmed by endoscopic biopsy and\u002For stage IB3-IIIC (FIGO 2018 staging) with large cervical tumors (maximum diameter ≥ 6 cm) and\u002For large lymph nodes (maximum short diameter of cross-section ≥ 2 cm) and\u002For ≥ 3 lymph node metastases confirmed by CT\u002FMR\u002FPET.\n\n  4\\. Female patients aged ≥ 18 years and ≤ 75 years. 5. KPS ≥ 70. 6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.\n\n  7\\. Expected survival of more than 6 months. 8. No previous radiotherapy, chemotherapy, immunotherapy or targeted therapy. 9. Major organ functions meet the following requirements: Absolute neutrophil count ≥ 1.5×109\u002FL, platelet count ≥ 80×109\u002FL, hemoglobin ≥ 80g\u002FL; Total bilirubin level ≤ 1.5 times the upper limit of normal (ULN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN; Serum creatinine ≤ 1.5 times ULN or creatinine clearance rate ≥ 60 ml\u002Fmin; Serum albumin ≥ 28g\u002FL; thyroid stimulating hormone (TSH) ≤ 1×ULN (if abnormal, FT3 and FT4 levels should also be examined. If FT3 and FT4 levels are normal, the subject can be enrolled).\n\n  10\\. Subjects agree to use effective contraceptive measures from the time of signing the informed consent until 180 days after the last dose. Women of childbearing age must not be pregnant or lactating.\n\n  11\\. All subjects must be willing to provide tumor tissue samples, blood samples, urine samples, fecal samples, and vaginal secretion samples after enrollment.\n\nExclusion Criteria:\n\n1. Other histopathological findings such as neuroendocrine carcinoma, sarcoma, gastric-type adenocarcinoma, and malignant melanoma components;\n2. Previous receipt of anti-tumor treatment related to cervical cancer;\n3. Evidence of distant metastasis, including lymph node metastasis in the groin, supraclavicular, and axillary regions;\n4. Previous total hysterectomy or subtotal hysterectomy;\n5. Anatomical abnormalities or contraindications that preclude the use of brachytherapy;\n6. Previous receipt of any treatment targeting tumor immune mechanisms, such as immune checkpoint inhibitors (e.g., anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies) or antibodies targeting immune co-stimulatory factors (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40 targets);\n7. Patients with other tumors that require current treatment;\n8. Active or potentially recurrent autoimmune diseases, except for those that do not require systemic treatment: vitiligo, alopecia, psoriasis or eczema; hypothyroidism caused by autoimmune thyroiditis, requiring stable doses of hormone replacement therapy; type 1 diabetes requiring stable doses of insulin replacement therapy;\n9. Patients currently using immunosuppressants or systemic hormones to achieve immunosuppression, and still using them within 2 weeks before enrollment;\n10. Poorly controlled clinical symptoms or diseases of the heart, such as (1) NYHA grade 2 or above heart failure; (2) unstable angina pectoris; (3) severe myocardial infarction within 1 year; (4) need for treatment or intervention for clinically significant supraventricular or ventricular arrhythmias; (5) QTc \\> 450 ms (male), QTc \\> 470 ms (female);\n11. Abnormal coagulation function (INR \\> 2.0, PT \\> 16s);\n12. Known hereditary or acquired bleeding disorders or thrombophilia (such as hemophilia patients, coagulation dysfunction, thrombocytopenia, etc.);\n13. Congenital or acquired immune deficiencies (such as HIV-infected individuals);\n14. Patients with HBV DNA \\> 2000 IU\u002Fml, or HCV RNA \\> 103, or HBsAg + anti-HCV antibody positive;\n15. Active infections that require treatment or use of systemic anti-infective drugs within one week before the first administration;\n16. Within 4 weeks before the first administration, received major surgical treatment or had significant trauma or required elective major surgical treatment during the study period.\n17. Hypertension, and unable to achieve good control with antihypertensive drugs (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg); previous occurrence of hypertensive crisis or hypertensive encephalopathy;\n18. Known that the patient was previously allergic to large molecule protein preparations. Has contraindications and allergies to epalorlimovalovirumab, cisplatin, carboplatin, paclitaxel, bevacizumab, any components thereof;\n19. Presence of abnormal results that may interfere with the test results, prevent the subject from fully participating in the study, or laboratory abnormalities that the investigator considers not in the best interests of the subject.",{"count":159,"type":20},46,[109],"This study is a single arm, phase II multicenter clinical trial to evaluate the efficacy and safety of the combination therapy of Iparomlimab and Tuvonralimab(QL1706) and chemotherapy ± bevacizumab induction therapy followed by concurrent chemoradiotherapy in patients with locally advanced cervical cancer at high risk of IVA stage and\u002For giant cervical tumors and\u002For giant metastatic lymph nodes and\u002For multiple metastatic lymph nodes.\n\nThe enrolled patients first receive 2 cycles of combined drug induction therapy: paclitaxel+cisplatin\u002Fcarboplatin ± bevacizumab+QL1706, every 3 weeks for 2 cycles; After induction therapy, synchronous radiotherapy and chemotherapy combined with immunotherapy: extracorporeal irradiation+post loading radiotherapy+synchronous chemotherapy+immunotherapy. During radiotherapy, single agent cisplatin\u002Fcarboplatin treatment for 5 courses per week+QL1706 treatment every 3 weeks for 3 courses; After the end of radiotherapy and chemotherapy, immune maintenance therapy will be administered for six months: treatment with QL1706 every 3 weeks for 9 courses, followed by a follow-up period until the end of radiotherapy for 2 years or death.",[163,29],"Cervical Cancer Stage IVA","2025-06-17",{"date":166,"type":44},"2025-06-25",{"date":168,"type":20},"2025-07-01",{"date":170,"type":20},"2029-12-31",{"name":172,"class":99},"Zhejiang Cancer Hospital"]